Severe pre-eclampsia
diseaseOn this page
Also known as Preeclampsia with severe featuressevere preeclampsia
Summary
Severe pre-eclampsia (MONDO:0001641) is a disease and 33 clinical trials. Top therapeutic interventions include labetalol, carbetocin, and eculizumab. A subtype of preeclampsia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 33
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | severe pre-eclampsia |
| Mondo ID | MONDO:0001641 |
| DOID | DOID:13129 |
| ICD-10-CM | O14.1 |
| ICD-11 | 479404771 |
| NCIT | C112843 |
| UMLS | C0341950 |
| MedGen | 574734 |
| GARD | 0022981 |
| Is cancer (heuristic) | no |
Also known as: Preeclampsia with severe features · severe preeclampsia
Disease family
This is a subtype of preeclampsia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › preeclampsia › severe pre-eclampsia
Related subtypes (6): mild pre-eclampsia, preeclampsia/eclampsia 2, preeclampsia/eclampsia 3, preeclampsia/eclampsia 4, preeclampsia/eclampsia 5, preeclampsia/eclampsia 1
Subtypes (1): HELLP syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 33.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 22 |
| PHASE4 | 4 |
| PHASE3 | 2 |
| PHASE2 | 2 |
| PHASE1/PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01408979 | PHASE4 | COMPLETED | Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia |
| NCT03164304 | PHASE4 | COMPLETED | Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia |
| NCT03872336 | PHASE4 | TERMINATED | Acute Labetalol Use in Preeclampsia |
| NCT03877692 | PHASE4 | TERMINATED | Acute Control of Chronic Hypertension |
| NCT07220902 | PHASE3 | NOT_YET_RECRUITING | Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure |
| NCT01382732 | PHASE3 | UNKNOWN | Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia |
| NCT03008616 | PHASE2/PHASE3 | TERMINATED | Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia |
| NCT06486025 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Protocols for Magnesium Sulfate Maintenance Dose in Overweight and Obese Women Diagnosed With Preeclampsia |
| NCT01766089 | PHASE2 | COMPLETED | Dexmedetomidine vs. Remifentanil for Pre-eclampsia During Caesarean Delivery |
| NCT02314286 | PHASE1/PHASE2 | UNKNOWN | Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery |
| NCT04725812 | PHASE2 | TERMINATED | Complement Regulation to Undo Systemic Harm in Preeclampsia |
| NCT07265336 | Not specified | RECRUITING | Excess Base Comparison Between Pregnant Subjects With Severe Preeclampsia vs. Normotensive Pregnant Women |
| NCT07547046 | Not specified | NOT_YET_RECRUITING | Factors Associated With Blood Pressure Control Failure to Intravenous Labetalol in Severe Preeclampsia |
| NCT01538121 | Not specified | UNKNOWN | Antiphospholipid Antibodies and Early Severe Preeclampsia. |
| NCT01538147 | Not specified | COMPLETED | Restless Leg Syndrome and Severe Preeclampsia |
| NCT01906567 | Not specified | UNKNOWN | İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels? |
| NCT02164370 | Not specified | COMPLETED | Evaluation of Metabolic Acid-base Abnormalities in Pre-eclamptic Women Applying the Stewart-Fencl Approach |
| NCT02189148 | Not specified | COMPLETED | First-trimester Prediction of Preeclampsia |
| NCT02379832 | Not specified | COMPLETED | Pre-Eclampsia And Growth Restriction: a Longitudinal Study |
| NCT03661775 | Not specified | COMPLETED | Serum Magnesium Level Administration in Severe Pre-eclampsia Obese Pregnancy |
| NCT03744988 | Not specified | UNKNOWN | Serum Androgen Levels as a Marker for the Severity of Preeclampsia |
| NCT04058405 | Not specified | COMPLETED | Risk Prediction Models for Adverse Maternal and Neonatal Outcomes in Preeclampsia |
| NCT04474704 | Not specified | COMPLETED | Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia |
| NCT05096728 | Not specified | COMPLETED | Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI) |
| NCT05176652 | Not specified | UNKNOWN | Ultrasonographic Diameter of Optic Nerve Sheath in Fluid Assessment in Severe Preeclamptic Patients |
| NCT05283473 | Not specified | COMPLETED | Serum Magnesium Concentration in Magnesium Sulfate Therapy for Severe Preeclampsia |
| NCT05310929 | Not specified | COMPLETED | Nitroglycerin Versus Labetalol in Acute Severe Pre-eclampsia |
| NCT06126068 | Not specified | COMPLETED | Comparison of Loading Dose Magnesium Sulphate With Prichard Regimen in the Management of Severe Preeclampsia and Eclampsia. |
| NCT06219109 | Not specified | UNKNOWN | Pulmonary Edema Resolution in Severe Preeclampsia and Eclampsia |
| NCT06265415 | Not specified | UNKNOWN | Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine |
| NCT06385600 | Not specified | UNKNOWN | Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia. |
| NCT07125599 | Not specified | COMPLETED | The Association Between Different Markers With Development of Maternal and Neonatal Complications in Women With Severe Preeclampsia |
| NCT07190846 | Not specified | COMPLETED | Diastolic Dysfunction 2025 |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LABETALOL | 4 | 3 |
| CARBETOCIN | 4 | 1 |
| ECULIZUMAB | 4 | 1 |
| LEVETIRACETAM | 4 | 1 |
| MAGNESIUM SULFATE | 4 | 1 |
| NIFEDIPINE | 4 | 1 |
| OXYTOCIN | 4 | 1 |
| PHENTOLAMINE | 4 | 1 |
| MAGNESIUM | 3 | 2 |
| ETIRACETAM | 2 | 1 |
| CHEMBL4303358 | 0 | 1 |
| LEVITIRACETAM | 0 | 1 |
Related Atlas pages
- Drugs: Labetalol, Carbetocin, Eculizumab, Levetiracetam, Magnesium, Nifedipine, Oxytocin, Phentolamine, Magnesium